streptodornase
Deoxyribonuclease refers to a group of glycoprotein endonucleases which are enzymes that catalyze the hydrolytic cleavage of phosphodiester linkages in the DNA backbone, thus degrading DNA. The role of the DNase enzyme in cells includes breaking down extracellular DNA (ecDNA) excreted by apoptosis, necrosis, and neutrophil extracellular traps (NET) of cells to help reduce inflammatory responses that otherwise are elicited. A wide variety of deoxyribonucleases are known and fall into one of two families, which differ in their substrate specificities, chemical mechanisms, and biological functions. Laboratory applications of DNase include purifying proteins when extracted from prokaryotic organisms. Additionally, DNase has been applied as a treatment for diseases that are caused by ecDNA in the blood plasma. Assays of DNase are emerging in the research field as well. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Nov 2, 2018 (NCT04252963)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDeoxyribonuclease ↗
- ChEMBLCHEMBL2108867 ↗
Also known as
- streptodornase
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04252963 | Phase 4 | Nov 2, 2018 | Hanmi Pharmaceutical, Konkuk University |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 1 | 1 | 1 | 2018 |
| Konkuk University | Academic/Hospital | 1 | 0 | 1 | 2018 |